Document:

Exhibit 4.1

 

EXHIBIT 4.1

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “1933 ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, ASSIGNED, TRANSFERRED OR
OTHERWISE DISPOSED OF, UNLESS REGISTERED PURSUANT TO THE PROVISIONS OF THAT ACT OR A SATISFACTORY
OPINION OF COUNSEL IS OBTAINED STATING THAT SUCH DISPOSITION IS IN COMPLIANCE WITH AN AVAILABLE
EXEMPTION FROM SUCH REGISTRATION.

VOID AFTER 5:00 P.M. EASTERN TIME ON DECEMBER 31, 2006

ADVENTRX Pharmaceuticals, Inc.

(fka BioQuest, Inc.)

(Incorporated under the laws of the State of Delaware)

Warrant for the Purchase of Shares of Common Stock

			
	No. WA-5
	 	Dated as of June 10, 1999

(Reissued as of April 6, 2006

to replace lost original)

FOR VALUE RECEIVED, ADVENTRX Pharmaceuticals, Inc. (the “Company”), a Delaware corporation
formerly known as BioQuest, Inc., hereby certifies that M. Ross Johnson or his permitted
assigns (collectively referred to as the “Holder”) is entitled, subject to the provisions of
this Warrant, to purchase from the Company, during the period commencing on the date of this
Warrant and expiring at 5:00 p.m. Eastern Time on June 9, 2006 (the “Expiration Date”) up to
Five Hundred Two Thousand Five Hundred Twenty-eight (502,528) fully
paid and non-assessable shares of the Company’s Common Stock (the “Warrant Shares”), at an exercise price of $0.49
per share (the “Exercise Price”), subject to adjustment as set forth below.

The term “Common Stock” means, unless the context otherwise indicates, the Common Stock of
the Company as constituted on the date hereof (the “Base Date”). The number of shares of
Common Stock to be received upon the exercise of this Warrant, and the Exercise Price, may
be subject to adjustment from time to time as hereinafter set forth. The term “Company”
means, unless the context otherwise indicates, the corporation named above as well as (i)
any immediate or more remote successor corporation resulting from the merger or
consolidation of the Company (or any immediate or more remote successor corporation of the
Company) with another corporation, or (iii) any corporation to which the Company (or any
immediate or more remote successor corporation of the Company) has transferred its property
or assets as an entirety or substantially as an entirety.

 

 

The Holder agrees with the Company that this Warrant is issued, and all the rights hereunder
shall be held subject to, all of the conditions, limitations and provisions set forth
herein.

     1. Expiration of Warrant. The Warrant shall expire at 5:00 p.m. Eastern Time on the
Expiration Date or, if such date is a day on which banking institutions in New York are authorized
by law to close, then on the next succeeding day that shall not be such a day.

     2. Exercise of Warrant.

          a. This Warrant may be exercised in whole or in part at any time after the date hereof or at
any other time as specifically provided for herein, by presentation and surrender of this Warrant
to the Company at its principal office, r at the office of its stock transfer agent, if any, with
the Warrant Exercise Form attached hereto duly executed and accompanied by payment (either in cash
or by certified or official bank check, payable to the order of the Company) of the Exercise Price
for the number of shares specified in such form, together with instruments of transfer, if
appropriate, duly executed by the Holder or his or her duly authorized attorney. If this Warrant
should be exercised in part only, the Company shall, upon surrender of this Warrant for
cancellation, execute and deliver a new Warrant, subject to all of the conditions, limitations, and
provisions set forth herein, evidencing the rights of the Holder thereof to purchase the balance of
the shares purchasable hereunder. Upon receipt by the Company of this Warrant, together with
payment of the Exercise Price, at its office, or by the stock transfer agent of the Company at its
office, in proper form for exercise, the Holder shall be deemed to be the holder of record of the
shares of Common Stock issuable upon such exercise, notwithstanding that the stock transfer books
of the Company shall then be closed or that certificates representing such shares of Common Stock
shall not then be actually delivered to the Holder. The Holder shall pay any and all documentary
stamp or similar issue or transfer taxes payable in respect of the issue or delivery of shares of
Common Stock on exercise of this Warrant.

          b. As an alternative to payment of the aggregate Exercise Price in accordance with paragraph
(a) above, Holder may elect to effect a cashless exercise by so indicating on the Warrant Exercise
Form attached hereto and including a calculation of the number of shares of Common Stock to be
issued upon such exercise in accordance with the terms hereof (a “Cashless Exercise”). In the
event of a Cashless Exercise, the Holder shall surrender this Warrant for that number of shares of
Common Stock determined by (i) multiplying the number of Warrant Shares for which this Warrant is
being exercised by the difference between the bid price of a share of Common Stock and the Exercise
Price, as of the trading day immediately before the date of exercise, and (ii) dividing the product
by the bid price of one share of Common Stock on the trading day immediately preceding the date of
exercise.

          c. The Holder may not exercise this Warrant to the extent that the number of Warrant Shares to
be received pursuant to such exercise, aggregated with all other shares of Common Stock then owned
by the Holder beneficially or deemed beneficially owned by the Holder, would result in the Holder
owning more than 9.9% of all of such Common Stock as would be outstanding on such date, as
determined in accordance with Section 16 of the Exchange Act and the rules and regulations
promulgated thereunder.

2

 

     3. Reservation of Shares. The Company with at all times reserve for issuance and
delivery upon exercise of this Warrant all shares of Common Stock or other shares of capital stock
of the Company (and other securities) from time to time receivable upon exercise of this Warrant.
All such shares (and other securities) shall be duly authorized and, when issued upon such
exercise, shall be validly issued, fully paid and non-assessable and free of all preemptive rights.

     4. Fractional Shares. No fractional shares or scrip representing fractional shares
shall be issued upon the exercise of this Warrant but, if the Holder is entitled to any fractional
share upon such exercise, the Company shall pay the Holder an amount equal to the fair market value
of such fractional share of Common Stock, in lieu of each fraction of a share otherwise called for
upon any exercise of this Warrant, as determined by the Company’s Board of Directors.

     5. Exchange, Transfer Assignment or Loss of Warrant. This Warrant is exchangeable,
without expense, at the option of the Holder, upon presentation and surrender hereof to the Company
or at the office of its stock transfer agent, if any, for other Warrants of different
denominations, entitling the Holder or Holders thereof to purchase in the aggregate the same number
of shares of Common Stock purchasable hereunder. Upon surrender of this Warrant to the company or
at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly
executed and funds sufficient to pay any transfer tax, the Company shall, without charge (but
subject to the restrictions on transfer set forth in Sections 11 and 12 below) execute and deliver
a new Warrant in the name of the assignee named in such instrument of assignment, and this Warrant
shall promptly be cancelled. This Warrant may be divided or combined with other Warrants that
carry the same rights upon presentation hereof at the office of the Company or at the office of its
stock transfer agent, if any, together with a written notice specifying the names and denominations
in which new Warrants are to be issued and signed by the Holder hereof.

     6. Rights of the Holder. The Holder shall not, by virtue hereof, be entitled to any
rights of a stockholder in the company, either at law or in equity, and the rights of the holder
are limited to those expressed in this Warrant.

          Adjustment Provisions.

          a. If the Company, at any time after the Base Date and prior to exercise of this Warrant,
shall have subdivided its outstanding shares of Common Stock (or other securities at the time
receivable upon the exercise of the Warrant) by recapitalization, reclassification or split-up
thereof, or if the Company shall have declared a stock dividend or distributed shares of Common
Stock to its stockholders, the number of Warrant Shares purchasable under this warrant immediately
prior to such exercise shall be proportionately increased, and if the Company, prior to such
exercise, shall have at any time combined the outstanding shares of Common Stock by
recapitalization, reclassification or combination thereof, the number of Warrant Shares subject to
this Warrant immediately prior to exercise shall be proportionately decreased.

          b. In case of any reorganization of the Company (or any other corporation, the securities of
which are at the time receivable on the exercise of this Warrant)
after the base

3

 

date or in case after such after such Base Date the Company (or any such other corporation)
shall consolidate with or merge into another corporation or convey all or substantially all of its
assets in another corporation, then, and in each such case, the Holder of this Warrant upon the
exercise thereof as provided in Section 2 above, at any time after the consummation of such
reorganization, consolidation, merger or conveyance, shall be entitled to receive the securities or
property to which such Holder would have been entitled upon such consummation if such Holder had
exercised this Warrant immediately prior thereto.

          c. Whenever the number of Warrant Shares purchasable upon the exercise of this Warrant is
required to be subject to adjustment, the Exercise Price shall be adjusted by multiplying the
Exercise Price in effect immediately prior to such adjustment by a fraction (x) the numerator of
which shall be the amount of Warrant Shares which would be purchasable upon exercise immediately
prior to such adjustment and (y) the denominator of which shall be the number of Warrant Shares so
purchasable immediately after such adjustment.

          d. The Company will not, by amendment of its Articles through reorganization, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms of the Warrant, but will at all times in
good faith assist in the carrying out all such terms and in the taking of all such action as may be
necessary or appropriate in order to protect the rights of the Holder of this Warrant. Without
limiting the generality of the foregoing, while any Warrant is outstanding, the Company:

	 	(i)	 	will not permit the par value, if any, of the shares of stock receivable upon the exercise of this Warrant to be
above the amount payable therefore upon such exercise; and
	 
	 	(ii)	 	will take all such action as may be necessary
or appropriate in order that the company may validly and legally issue
or sell fully paid and non-assessable stock upon the exercise of all
Warrants at the time outstanding.

          e. In case:

	 	(i)	 	the Company shall take a record of the holders
of its Common Stock (or other securities at the time receivable upon
the exercise of the Warrant) for the purpose of entitling them to
receive any dividend (other than a cash dividend at the same rate as
the rate of the last cash dividend theretofore paid) or other
distribution, or any right to subscribe for, purchase or otherwise
acquire any shares of stock of any class or any other securities, or to
receive any other right; or
	 
	 	(ii)	 	of any capital reorganization of the Company,
any reclassification of the capital stock of the Company, any
consolidation or merger of the Company with or into another
corporation, or any

4

 

	 	 	 	conveyance of all or substantially all of the assets of the Company
to another corporation; or
	 
	 	(iii)	 	of any voluntary or involuntary dissolution,
liquidation or winding up of the Company; or
	 
	 	(iv)	 	any other event specified to this Section 9
requiring the taking of such a record.

     Then, and in each such case, the Company shall mail or cause to be mailed to each holder of
any Warrant at the time outstanding a notice specifying, as the case may be, the date on which a
record is to be taken for the purpose of such dividend, distribution or right, and stating the
amount and character of such dividend, distribution or right, or the date on which such
reorganization, reclassification, consolidation, merger, conveyance, dissolution, liquidation or
winding up is to take place, and the time, if any, to be fixed, as to which the holders of record
of Common Stock (or such other securities at the time receivable upon the exercise of the Warrant)
shall be entitled to exchange their shares of Common Stock (or such other securities) for
securities or other property deliverable upon such reorganization, reclassification, consolidation,
merger, conveyance, dissolution, liquidation or winding up. Such notice shall be mailed at least
twenty days prior to the record date therein specified and this Warrant may then be exercised prior
to said record date during the term of the Warrant and without regard to any waiting period which
may be set forth under any other provision of this Warrant.

     8. Registration Rights.

          a. If the Company proposes, at any time prior to the Expiration Date to file a registration
statement with the Securities and Exchange Commission (the “Commission”) on a Form S-1 or
comparable general form for registration under the 1993 Act and relating to securities issued or to
be issued by it, then it shall give written notice of such proposed filing to the Holder. If,
within thirty days after the giving of such notice, the Holder shall request in writing that all or
any of the Warrant Shares be included in such proposed registration, the Company will also register
such shares as shall have been requested in writing. While the registration of such Warrant Shares
will not require the exercise of the Warrant prior to the effective date of such registration, The
Holder will be required to demonstrate a bona fide present intention to sell the Warrant Shares
being registered promptly after the registration statement becomes effective, failing which the
company may take steps to withdraw such Warrant Shares from registration. If all such Warrant
Share have been so registered, the rights described in Section 8(b) below shall be of no force or
effect. The provisions of this paragraph a. shall not apply to a registration statement filed in
connection with an initial public offering by the Company.

          b. In addition, if by September 15, 2000, the Company has not filed with the Commission a
registration statement covering shares of Common Stock, Holder may give notice to the Company at
any time after September 15, 2000 and prior to the Expiration date to the effect that such Holder
desires to register, for sale under the 1933 Act, any Warrant Shares in which case the Company will
promptly, on one occasion only, no later than 90 days after receipt of such notice file a
post-effective amendment to any current registration statement or a new

5

 

registration statement to the end that the Warrant Shares designated in such notice may be
publicly sold under the 1933 Act as promptly as practicable thereafter, and the Company will use
its best effort to cause such registration statement to become and remain effective (including the
taking of such steps as are necessary to obtain the removal of any stop order); provided
however, that the Holder shall furnish the Company with such appropriate information in
connection therewith as the company may reasonably request in writing.

          c. The Holder may give the notice requiring the filing of a registration statement under the
Act as set forth in Subsection above on not more than one occasion prior to the Expiration Date.

          d. In connection with the filing of a registration statement pursuant to this Section 8, the
Company shall:

	 	(i)	 	notify such Holder as to the filing and status
thereof and of all amendments thereto filed prior to the effective date
of said registration statement;
	 
	 	(ii)	 	notify such Holder promptly after it shall have
received notice of the time when the registration statement becomes
effective or any supplement to any prospectus forming a part of the
registration statement has been filed;
	 
	 	(iii)	 	prepare and file without expense to such
holder any necessary amendment or supplement to such registration
statement or prospectus as may be necessary to comply with the 1933 Act
or advisable in connection with the proposed distribution of the
securities of such Holder;
	 
	 	(iv)	 	take all reasonable steps to qualify the
Warrant Shares for sale under the securities or blue sky Jaws of such
reasonable number of states as such Holder may designate in writing and
to register or obtain the approval of any federal or state authority
which may be required in connection with the proposed distribution,
except, in each case, in jurisdictions in which the Company must either
qualify to do business or file a general consent to service of process
as a condition of the qualification of such securities;
	 
	 	(v)	 	notify such Holder of any stop order suspending
the effectiveness of the registration statement and use its reasonable
best efforts to remove such stop order;
	 
	 	(vi)	 	undertake to keep such registration statement
and prospectus effective for a period of one year after its effective
date;
	 
	 	(vii)	 	furnish to such Holder as soon as available,
copies of any such registration statement and each preliminary or final
prospectus and any supplement or amendment required to be prepared
pursuant to

6

 

	 	 	 	the foregoing provisions of this Section, all in such quantities as
such Holder may from time to time reasonably request.

          e. The Holder agrees to pay any underwriting discounts and commissions, transfer taxes,
registration fees and the Holder’s own counsel fees with respect to the Warrant Shares being
registered. The Company will pay all other costs and expenses in connection with a registration
statement to be filed pursuant to this Section 8, including, without limitation, the fees and
expenses of counsel for the Company, the fees and expenses of its accountants, and all other costs
and expenses incident to the preparation, printing and filing under the Act of any such
registration statement, each prospectus and all amendments and supplements thereto, the costs
incurred in connection with the qualification of such securities for sale in such reasonable number
of states as the Holder have designated, including fees and disbursements of counsel for the
Company, and the costs of supplying a reasonable number of copies of the registration statement,
each preliminary prospectus, final prospectus and any supplements or amendments thereto to such
Holder.

          f. The Company agrees to enter into an appropriate cross-indemnity agreement with any
underwriter (as defined in the 1933 Act) for such holder in connection with the filing of a
registration statement pursuant to this Section.

          g. If the Company shall file any registration statement including therein all or any part of
the shares of the Company’s Common Stock held by the Holder, the Company and each Holder shall
enter into an appropriate cross-indemnity agreement whereby the Company shall indemnify and hold
harmless the Holder against any losses, claims, damages or liabilities (or actions in respect
thereof) arising out of or based upon any untrue statement or alleged untrue statement of any
material fact contained in such registration statement, or any omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make statements therein
not misleading unless such statement or omission was made in reliance upon and in conformity with
written information furnished or required to be furnished by any such Holder, and each such holder
shall indemnify and hold harmless the Company, each of its directors and officers who have signed
the registration statement and each person, if any, who controls the Company; within the meaning of
the 1933 Act against any losses, claims, damages or liabilities (or actions in respect thereof)
arising out of or based upon any untrue statement or alleged untrue statements therein not
misleading if the statement or omission was made in reliance upon and in conformity with written
information furnished or required to be furnished by such Holder expressly for use in such
registration statement.

          h. Anything to the contrary herein notwithstanding, if all of the shares of the Company’s
Common Stock then held by the Holder may be sold by the Holder thereof in a transaction pursuant to
Rule 144 promulgated under the 1933 Act, the Holder shall not be entitled to require the Company to
register such securities pursuant to any registration statement filed under the 1933 Act.

          i. For a period of one year after the effective date of the registration statement filed
pursuant to this Section 8, the Company at its expense will file such post-effective amendments as
may be necessary to make available for use a prospectus meeting the requirements of the 1933 Act.
The Company will cause copies of such prospectus to be

7

 

delivered to any person selling the shares of Common Stock as may be required by the 1933 Act
and the rules and regulations of the Commission.

          j. If a managing underwriter acting in good faith determines that the inclusion of all or any
part of the Warrant Shares in a registration statement would adversely affect the marketing of
securities intended to be underwritten, the amount of such Warrant Shares to be registered shall be
reduced or limited to the amount which the underwriter, in its discretion, reasonably exercised in
good faith, determines would not adversely affect the successful marketing of the underwritten
securities. As an alternative, such underwriter may request that the sale of any Warrant Shares
included in a registration statement on behalf of a holder be delayed for a period of up to nine
months after the conclusion of the distribution of securities to be offered on behalf of the
Company, and, upon receipt of such request, such Holder shall execute an agreement to such effect
as a condition of inclusion in such registration statement.

     9. Restrictions on Transfer; All Transfers to Comply with the 1933 Act, etc. Prior to
the registration of the Warrant Shares as set forth in Section 8, or the sale of sale of such
Warrant Shares pursuant to Rule 144 of the Commission, this Warrant and any Warrant Shares may not
be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of except to members of
the immediate family of M. Ross Johnson, unless otherwise agreed by the Board of Directors of the
Company. Until such registration or sale pursuant to Rule 144, this Warrant and the Warrant Shares
may be transferred to other persons, but only with the approval of the Board of Directors of the
Company. Each transferee of this Warrant or any Warrant Shares must be: (1) a person who, in the
opinion of counsel to the Company, is a person to whom this Warrant or the Warrant Shares may
legally be transferred without registration and without the delivery of a current prospectus under
the 1933 Act with respect thereto, and then only against receipt of (i) requested information
concerning the status of such person and such transfer under federal and state securities laws and
(ii) the agreement of such person to comply with the provisions of this Section 9 with respect to
any resale or other disposition of such securities; or (2) a person to whom delivery is made of a
prospectus then meeting the requirements of the 1933 Act relating to such securities and such sale
or disposition, and thereafter to all successive assignees. The Company reserves the right to
require an opinion of counsel for the Holder with respect to any proposed transfer other than
transfers made pursuant to a registered securities offering.

     10. Legend. Unless the Warrant Shares have been registered under the 1933 Act, upon
exercise of the Warrant and the issuance of any of the Warrant Shares, all certificates
representing such shares shall bear on the face thereof substantially the following legend:

The securities represented by this certificate have not been registered under the
Securities Act of 1933, as amended, and may not be sold, offered for sale, assigned,
transferred or otherwise disposed of, unless registered pursuant to the provisions
of that Act or unless an opinion of counsel to the Corporation is obtained stating
that such disposition is in compliance with an available exemption from such
registration.

     11. Notices. All notices required hereunder shall be in writing and shall be deemed
given when transmitted (with verified receipt), delivered personally or mailed by certified or

8

 

registered mail, return receipt requested, to the Company or Holder, as the case may be, for
whom such notice is intended, to the address of such party of which the Company or Holder has been
advised by written notice.

     12. Applicable Law. The Warrant is issued under and shall for all purposes be
governed by and construed in accordance with the laws of the State of Delaware.

     13. Loss of Warrant Certificate. Upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and (in the case
of loss, theft or destruction) of reasonably satisfactory indemnification, and upon surrender and
cancellation of this Warrant, if mutilated, the company shall execute and deliver a new Warrant of
like tenor and date. Any such new Warrant executed and delivered shall constitute an additional
contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen,
destroyed or mutilated shall be at any time enforceable by anyone.

     IN WITNESS WHEREOF, the Company has caused this Warrant to be signed in its behalf, in its
corporate name, by its duly authorized officer, all as of the day and year first above written.

	 	 	 	 	 	 	 	 	 
	Dated:	 	June 10, 1999	 	ADVENTRX Pharmaceuticals, Inc.	 	 
	 	 	(Reissued as of April 6, 2006	 	a Delaware corporation	 	 
	 	 	to replace lost original)	 	(formerly known as BioQuest, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:
	/s/ Carrie E. Carlander
 

	 	 
	 	 	 	 	Name: Carrie E. Carlander	 	 
	 	 	 	 	Its: Chief Financial Officer	 	 

9

 

WARRANT EXERCISE FORM

     The undersigned hereby irrevocably elects to exercise the within Warrant to the extent of
purchasing
                     shares of Common Stock of ADVENTRX Pharmaceuticals, Inc. (formerly known as
BioQuest, Inc.) and hereby makes payment of $                                         representing the aggregate Exercise Price
required by connection therewith. The undersigned also surrenders the Warrant certificate to be
processed in accordance with the terms set forth therein.

	 	 	 	 	 
	 

	 	 

Signature
	 	 
	 
	 	 	 	 
	 

	 	 

Signature, if jointly held
	 	 
	 
	 	 	 	 
	 

	 	 

Print Name or Names
	 	 
	 
	 	 	 	 
	 

	 	 

Date
	 	 

INSTRUCTIONS FOR ISSUANCE OF STOCK

(if other than to the registered holder of the within Warrant)

	 	 	 	 	 
	Name
	 	 	 	 
	 

	 	 

(Please typewrite or print in block letters)
	 	 
	Address
	 	 	 	 
	 

	 	 

	 	 
	Social Security or
Taxpayer Identification Number
	 

	 	 

	 	 

10Exhibit 4.2

 

EXHIBIT 4.2

THIS WARRANT HAS BEEN, AND THE SHARES OF COMMON STOCK WHICH MAY BE RECEIVED PURSUANT TO THE
EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR
RESALE IN CONNECTION WITH, ANY DISTRIBUTION THEREOF. NEITHER THIS WARRANT NOR SUCH SHARES
(TOGETHER, THE “SECURITIES”) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR QUALIFICATION OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT
SUCH DISPOSITION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT
AND ANY REGISTRATION OR QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE SECURITIES LAWS.

			
	 
	No. WC-303
	 	Dated as of April 12, 2002

Warrant to Purchase Common Stock

 

     This certifies that, for good and valuable consideration, Emisphere Technologies, Inc. (the
“Holder”) is entitled to purchase from ADVENTRX Pharmaceuticals, Inc., a Delaware corporation
formerly known as Biokeys Pharmaceuticals, Inc. (the “Company”), Fifty Thousand (50,000) fully paid
and nonassessable shares of Common Stock, par value $0.001 per share (“Common Stock”), of the
Company (as adjusted pursuant to Section 3 hereof) (the “Warrant Shares”) at a price per share
equal to Two Dollars and Fifty Cents ($2.50) (as adjusted pursuant to Section 3 hereof) (the
“Exercise Price”), subject to the provisions and upon the terms and conditions hereinafter set
forth.

1. Exercise; Payment.

     (a) Exercise Period. This Warrant may be exercised in whole or part by the Holder
during the term (as set forth in Section 9) and in compliance with the provisions of this
Warrant at any time after the date of issuance set forth above (the “Warrant Date”), by the
surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A
(the “Notice of Exercise”) duly executed) at the principal office of the Company. If this
Warrant shall have been exercised in part, the Company shall, at the time of delivery of the
certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased shares of Common Stock called
for by this Warrant, which new Warrant shall in all other respects be identical with this
Warrant, or at the request of the Holder, appropriate notation may be made on this Warrant and
the same returned to the Holder.

     (b) Means of Exercise. Upon exercise of this Warrant, the Holder shall pay the
Company an amount equal to the product of (x) the Exercise Price
multiplied by (y) the total
number of Warrant Shares purchased pursuant to this Warrant, by wire transfer or cashier’s check
payable to the order of the Company. The Holder shall be deemed to have become the

 

 

holder of record of, and shall be treated for all purposes as the record holder of, the
Warrant Shares represented thereby (and such Warrant Shares shall be deemed to have been issued)
immediately prior to the close of business on the date upon which this Warrant is exercised.

     (c) Stock Certificates. In the event of the exercise of this Warrant, certificates
for the Warrant Shares so purchased shall be delivered to the Holder within a reasonable time
after exercise.

2. Stock Fully Paid; Reservation of Shares. All of the Warrant Shares issuable upon the exercise
this Warrant will, upon issuance and receipt of the Exercise Price therefor, be fully paid and
nonassessable, and free from all preemptive rights, rights of first refusal or first offer, taxes,
liens and charges with respect to the issuance thereof. During the period within which the rights
represented by this Warrant may be exercised, the Company shall at all times have authorized and
reserved for issuance a sufficient number of shares of its Common Stock to provide for the exercise
of this Warrant.

3. Adjustment of Exercise Price and Number of Shares. The number and kind of Warrant Shares
purchasable upon the exercise of this Warrant and the Exercise Price payable therefor shall be
subject to adjustment from time to time upon the occurrence of certain events, as follows:

     (a) Reclassification, Consolidation or Reorganization. In case of any
reclassification of the Common Stock (other than a change in par value, or as a result of a
subdivision or combination), or in case of any consolidation or merger of the Company with or
into another corporation (other than a Change of Control, as defined below) (any of which is a
“Reorganization Transaction”), the Company, or such successor corporation as the case may be,
shall execute a new warrant, providing that the Holder shall have the right to exercise such new
warrant, and procure upon such exercise and payment of the same aggregate Exercise Price, in
lieu of the Warrant Shares theretofore issuable upon exercise of this Warrant, the kind and
amount of shares of stock, other securities, money and property as would be payable for the
Warrant Shares issuable upon exercise of this Warrant as if such Warrant Shares were outstanding
immediately prior to the consummation of the Reorganization Transaction. For purposes of this
Warrant, the term “Change of Control” shall mean (i) any acquisition of the Company by means of
merger, acquisition, or other form of corporate reorganization in which outstanding shares of
the Company are exchanged for securities or other consideration issued, or caused to be issued,
by the acquiring corporation or its subsidiary or parent (other than a reincorporation
transaction or change of domicile) and pursuant to which the holders of the outstanding voting
securities of the Company immediately prior to such consolidation, merger or other transaction
fail to hold equity securities representing a majority of the voting power of the Company or
surviving entity immediately following such consolidation, merger or other transaction
(excluding voting securities of the acquiring corporation held by such holders prior to such
transaction) or (ii) a sale of all or substantially all of the assets of the Company.

     (b) Stock Splits, Dividends and Combinations. In the event that the Company shall
at any time subdivide the outstanding shares of Common Stock, or shall issue a stock dividend on
its outstanding shares of Common Stock, the number of Warrant Shares issuable upon

2

 

exercise of this Warrant immediately prior to such subdivision or to the issuance of such
stock dividend shall be proportionately increased, and the Exercise Price shall be
proportionately decreased, and in the event that the Company shall at any time combine the
outstanding shares of Common Stock, the number of Warrant Shares issuable upon exercise of this
Warrant immediately prior to such combination shall be proportionately decreased, and the
Exercise Price shall be proportionately increased, effective at the close of business on the
date of such subdivision, stock dividend or combination, as the case may be.

     (c) Notice of Corporate Action. If at any time:

(i) the Company shall take a record of the holders of its Common Stock for the
purpose of entitling them to receive a dividend (other than a cash dividend payable
out of earnings or earned surplus legally available for the payment of dividends
under the laws of the jurisdiction of incorporation of the Company) or other
distribution, or any right to subscribe for or purchase any evidences of its
indebtedness, any shares of stock of any class or any other securities or property,
or to receive any other right, or

(ii) there shall be any capital reorganization of the Company, any reclassification
or recapitalization of the capital stock of the Company or any consolidation or
merger of the Company with, or any sale, transfer or other disposition of all or
substantially all the property, assets or business of the Company to, another
corporation, or

(iii) there shall be a voluntary or involuntary dissolution, liquidation or winding
up of the Company;

then, in any one or more of such cases, the Company shall give to the Holder (i) at least
five-days’ prior written notice of the date on which a record date shall be selected for
such dividend, distribution or right or for determining rights to vote in respect of any
such reorganization, reclassification, merger, consolidation, sale, transfer, disposition,
dissolution, liquidation or winding up, and (ii) in the case of any such reorganization,
reclassification, merger, consolidation, sale, transfer, disposition, dissolution,
liquidation or winding up, at least five-days’ prior written notice of the date when the
same shall take place. Such notice in accordance with the foregoing clause also shall
specify (i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, the date on which the holders of Common Stock shall be
entitled to any such dividend, distribution or right, and the amount and character thereof,
and (ii) the date on which any such reorganization, reclassification, merger, consolidation,
sale, transfer, disposition, dissolution, liquidation or winding up is to take place and the
time, if any such time is to be fixed, as of which the holders of Common Stock shall be
entitled to exchange their shares of Common Stock for securities or other property
deliverable upon such reorganization, reclassification, merger, consolidation, sale,
transfer, disposition, dissolution, liquidation or winding up. Each such written notice
shall be sufficiently given if addressed to the Holder at the last address of the Holder
appearing on the books of the Company and delivered in accordance with Section 10(d).

3

 

4. Transfer of Warrant and Resale of Warrant Shares.

     (a) This Warrant may only be transferred in compliance with federal and state securities
laws; provided, however, that the Company may withhold its consent to transfer
or assignment of this Warrant to any person or entity who is deemed to be a competitor or
prospective competitor of the Company, such determination to be made in the reasonable judgment
of the Board of Directors of the Company.

     (b) At the time of the surrender of this Warrant in connection with any transfer of this
Warrant or the resale of the Warrant Shares, the Company may require, as a condition of allowing
such transfer (i) that the Holder or transferee of this Warrant or the Warrant Shares as the
case may be, furnish to the Company a written opinion of counsel that is reasonably acceptable
to the Company to the effect that such transfer may be made without registration under the
Securities Act of 1933, as amended (the “Securities Act”) or qualification under any state
securities laws, (ii) that the Holder or transferee execute and deliver to the Company an
investment representation letter in form and substance acceptable to the Company and
substantially in the form of Exhibit B hereto and (iii) that the transferee be an
“accredited investor” as defined in Rule 501(a) promulgated under the Securities Act. Transfer
of this Warrant and all rights hereunder, in whole or in part, in accordance with the foregoing
provisions, shall be registered on the books of the Company to be maintained for such purpose,
upon surrender of this Warrant at the principal office of the Company or the office or agency
designated by the Company, together with a written assignment of this Warrant substantially in
the form of Exhibit C hereto duly executed by the Holder or its attorney-in-fact and
funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or
Warrants in the name of the assignee or assignees and in the denomination specified in such
instrument of assignment, and shall issue to the Holder a new warrant evidencing the portion of
this Warrant not so assigned, and this Warrant shall be deemed cancelled. This Section 4 shall
survive the exercise or expiration of the Warrant.

5. Conditions to Exercise of Warrant.

     (a) Each certificate evidencing the Warrant Shares issued upon exercise of this Warrant
shall be stamped or imprinted with a legend substantially in the following form:

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED
OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH
OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.

     (b) Removal of Legend and Transfer Restrictions. Any legend endorsed on a certificate
pursuant to this Section 5 shall be removed, and the Company shall issue a certificate without
such legend to the holder of such Warrant Shares if (i) such Warrant

4

 

Shares are resold pursuant to a registration statement under the Securities Act and a
prospectus meeting the requirements of Section 11 of the Securities Act is delivered or deemed
delivered to the purchaser of such Warrant Shares, (ii) if such holder satisfies the
requirements of Rule 144(k) under the Securities Act or (iii) if such holder provides the
Company with an opinion of counsel for such holder of the Warrant Shares, reasonably
satisfactory to the Company, to the effect that a sale, transfer or assignment of such Warrant
Shares may be made without registration and that upon such sale, transfer or assignment such
Warrant Shares will not be deemed “restricted securities,” as such term is defined in Rule 144
under the Securities Act.

6. Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise
of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment
therefor upon the basis of the Exercise Price then in effect.

7. Rights of Stockholders. The Holder shall not be entitled to vote or receive dividends or be
deemed the holder of Warrant Shares or any other securities of the Company which may at any time be
issuable on the exercise of this Warrant for any purpose, nor shall anything contained herein be
construed to confer upon the Holder any of the rights of a stockholder of the Company or any right
to vote for the election of directors or upon any matter submitted to stockholders at any meeting
thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization,
issuance of stock, reclassification of stock, change of par value, consolidation, merger,
conveyance, or otherwise) or to receive dividends or subscription rights or otherwise with respect
to the Warrant Shares until this Warrant shall have been exercised and the Warrant Shares
purchasable upon the exercise of this Warrant shall have become deliverable, as provided in this
Warrant.

8. Registration Rights.

     (a) Piggy-back Rights. If (but without any obligation to do so) the Company
proposes to register any shares of Common Stock solely for cash pursuant to a registration
statement under the Securities Act, other than a registration solely for the sale of securities
to participants in a Company stock or other incentive plan or in connection with a transaction
under Rule 145 promulgated under the Securities Act (a “Public Offering”), the Company shall
promptly give the Holder written notice of such Public Offering, at least 10 business days prior
to the filing of the registration statement under the Securities Act regarding such Public
Offering. Upon the written request of the Holder given within 5 business days after delivery of
such written notice by the Company, the Company shall, subject to the provisions of this Section
8, use commercially reasonable efforts to cause to be registered for resale under the Securities
Act all of the Warrant Shares that the Holder has requested to be registered on such
registration statement, provided, that the Company shall have no obligation to register
such shares if applicable rules, regulations or other requirements of the Securities and
Exchange Commission prohibit the Company from including such Warrant Shares on such registration
statement on the form thereof used by the Company or require that the registration statement be
for (or meet all of the requirements of) a primary offering if such registration statement
pertains to a secondary offering.

5

 

     (b) Underwriting. If the registration statement under which the Company gives
notice under this Section 8 is for an underwritten Public Offering, the Company shall so advise
the Holder. The right of the Holder to registration pursuant to Section 8(a) above shall be
conditioned upon the Holder’s participation in such underwriting and the inclusion of the
Warrant Shares in the underwriting to the extent provided herein. The Holder shall (together
with the Company and any other holders of Company securities distributing their securities
through such underwriting) enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for underwriting by the Company. Notwithstanding any other
provision of this Section 8, if the underwriter determines that marketing factors require a
limitation of the number of shares to be underwritten, the underwriter may exclude some or all
of the Warrant Shares from such registration and underwriting.

     (c) Furnish Information. It shall be a condition to the Company’s obligations to
take any action under this Section 8 that the Holder shall promptly furnish to the Company such
information regarding itself, the Warrant Shares, and the intended method of disposition of such
Warrant Shares as shall be required to effect the registration of any Warrant Shares. In that
connection, the Holder shall be required to represent to the Company that all such information
which is given is both complete and accurate in all material respects when made.

     (d) Delay of Registration. The Holder shall have no right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any
controversy that might arise with respect to the interpretation or implementation of this
Section 8.

     (e) Termination of Registration Rights. The Company shall have no obligation to
register Warrant Shares pursuant to this Section 8 with respect to any request or requests made
by any Holder on or after that date which is one year after the date such Warrant Shares were
deemed to be acquired for purposes of determining the holding period of such Warrant Shares
under Rule 144 of the Securities Act.

9. (a) Term of Warrant. This Warrant shall become exercisable on the Warrant Date and shall no
longer be exercisable as of the earlier of (i) 5:00 p.m., San Diego, California local time, on the
date that is the five-year anniversary of the Warrant Date; (ii) immediately prior to the
consummation of a Change of Control and (iii) 5:00 p.m., San Diego, California local time, on the
Call Termination Date (as defined below).

6

 

     (b) Notwithstanding Section 9(a), the Company may, by at least 10-days’ prior written
notice to the Holder (the “Termination Notice”) which Termination Notice shall state the date
this Warrant shall terminate (the “Call Termination Date”), shall terminate this Warrant, at any
time, provided that the average Market Price over a 10-consecutive-trading-day period is
equal to or greater than the product of (x) 2 multiplied by (y) the Exercise Price,
provided, however, that the Company may not deliver a Termination Notice unless
a registration statement registering the Warrant Shares has been declared effective and is
effective from the date of delivery of the Termination Notice until the date this Warrant shall
terminate as set forth in the Termination Notice. Nothing in this Section 9 shall prevent the
exercise of the Warrants at any time prior to the termination of this Warrant. For purposes of
this Section 9(b) the term “Market Price” means (i) the closing price of a share of Common Stock
on the principal stock exchange or market (including the Nasdaq National Market, AMEX, OTCCBB
and NYSE) on which shares of Common Stock are then listed or admitted to trading, or quoted, as
applicable (the “Listing Market”), or (ii) if no sale takes place on such day on the Listing
Market, the last reported closing price on the Listing Market.

10. Miscellaneous.

     (a) This Warrant is being delivered in the State of California and shall be construed and
enforced in accordance with and governed by the laws of the State of California, without giving
effect to principles of conflicts of laws.

     (b) The headings in this Warrant are for purposes of reference only, and shall not limit or
otherwise affect any of the terms hereof.

     (c) The terms of this Warrant shall be binding upon and shall inure to the benefit of any
successors or assigns of the Company and of the Holder and of the Warrant Shares issued or
issuable upon the exercise hereof.

     (d) Any notice provided for or permitted under this Warrant shall be treated as having been
given (i) upon receipt, when delivered personally, (ii) one day after sending, when sent by
commercial overnight courier with written verification of receipt, (iii) upon confirmed
transmission when sent via facsimile on a business day prior to 5:00 pm (Pacific time) or, if
sent after 5:00 pm (Pacific time), the next business day after confirmed transmission or (iv)
three business days after deposit with the United States Postal Service, when mailed postage
prepaid by certified or registered mail, return receipt requested, addressed, if to the Company,
at 6725 Mesa Ridge Road, Suite 100, San Diego, CA 92121, (f) (858) 552-0876, Attention:
President, or, if to the Holder, at such address or facsimile number as the Holder shall have
furnished to the Company in writing, or at such other place of which the other party has been
notified in accordance with the provisions of this Section 10(d).

     (e) This Warrant constitutes the full and entire understanding and agreement between the
parties with regard to the subjects hereof.

     (f) Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and, in the case of any such loss, theft or
destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and

7

 

amount to the Company or, in the case of any such mutilation, upon surrender and
cancellation of such Warrant, the Company at the Holder’s expense will execute and deliver to
the holder of record, in lieu thereof, a new Warrant of like date and tenor.

     (g) This Warrant and any provision hereof may be amended, waived or terminated only by an
instrument in writing signed by the Company and the Holder.

     (h) Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to
the foregoing terms and conditions.

8

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by its duly authorized
officer, all as of the day and year first above written.

	 	 	 	 	 	 	 
	 	 	ADVENTRX Pharmaceuticals, Inc.,

a Delaware corporation formerly known as

Biokeys Pharmaceuticals, Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Evan M. Levine
 

Evan M. Levine
	 	 
	 

	 	 	 	President & CEO	 	 

Signature Page to Warrant to Purchase Common Stock

 

Exhibit A

Notice of Exercise

	 	 	 
	TO:

	 	ADVENTRX Pharmaceuticals, Inc.
	 

	 	6725 Mesa Ridge Road, Suite 100
	 

	 	San Diego, CA 92121

     The undersigned hereby elects to purchase ______shares of Common Stock, par value
$0.001 per share (“Common Stock”), of ADVENTRX Pharmaceuticals, Inc., a Delaware corporation
formerly known as Biokeys Pharmaceuticals, Inc. (the “Company”) pursuant to the terms of Section
1(b) of the Warrant to Purchase Common Stock dated April 12, 2002, (the “Warrant”), and tenders
herewith payment of the Exercise Price (as such term is defined in the Warrant) therefor.

     Please issue a certificate or certificates representing said ______shares of Common Stock
in the name of the undersigned or in such other name as is specified below:

	 	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Address:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 

	 	 

     The undersigned hereby represents and warrants that the aforesaid shares of Common Stock are
being acquired for the account of the undersigned for investment and not with a view to, or for
resale, in connection with the distribution thereof, and that the undersigned has no present
intention of distributing or reselling such shares.

	 	 	 	 	 	 	 
	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	 	 	 
	 

	 	Date:
	 	 

	 	 
	 

	 	 	 	 

	 	 

 

 ExhibitB

Form Of Investment Representation Letter

In connection with the acquisition of [warrants (the “Warrants”) to purchase                     
shares of Common Stock of ADVENTRX Pharmaceuticals, Inc. (the “Company”), par value $0.001
per share (the “Common
Stock”)][                     shares of Common Stock of ADVENTRX
Pharmaceuticals, Inc. (the “Company”), par value $0.001 per share (the “Common
Stock”)], by                                          (the “Holder”) from                                         , the Holder hereby
represents and warrants to the Company as follows:

The Holder (i) is an “Accredited Investor” as that term is defined in Rule 501 of Regulation D
promulgated under the Securities Act of 1933, as amended (the “Act”); and (ii) has the
ability to bear the economic risks of such Holder’s prospective investment, including a complete
loss of Holder’s investment in the Warrants and the shares of Common Stock issuable upon the
exercise thereof (collectively, the “Securities”).

The Holder, by acceptance of the Warrants, represents and warrants to the Company that the Warrants
and all securities acquired upon any and all exercises of the Warrants are purchased for the
Holder’s own account, and not with view to distribution of either the Warrants or any securities
purchasable upon exercise thereof in violation of applicable securities laws.

The Holder acknowledges that (i) the Securities have not been registered under the Act, (ii) the
Securities are “restricted securities” and the certificate(s) representing the Securities shall
bear the following legend, or a similar legend to the same effect, until (i) in the case of the
shares of Common Stock underlying the Warrants, such shares shall have been registered for resale
by the Holder under the Act and effectively been disposed of in accordance with a registration
statement that has been declared effective; or (ii) in the opinion of counsel for the Company such
Securities may be sold without registration under the Act:

“[NEITHER] THE SECURITIES REPRESENTED BY THIS CERTIFICATE [NOR THE SECURITIES INTO WHICH THEY ARE
EXERCISABLE] HAVE [NOT] BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
AND ALL SUCH SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AS SET FORTH IN THIS
CERTIFICATE. [NEITHER] THE SECURITIES REPRESENTED HEREBY [NOR THE SECURITIES INTO WHICH THEY ARE
EXERCISABLE] MAY [NOT] BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO
COUNSEL FOR THE COMPANY, TO THE EFFECT THAT THE PROPOSED SALE, TRANSFER, OR DISPOSITION MAY BE
EFFECTUATED WITHOUT REGISTRATION UNDER THE ACT.”

IN WITNESS WHEREOF, the Holder has caused this Investment Representation Letter to be executed in
its corporate name by its duly authorized officer this ___day of                      200_.

[Name]

	 	 	 	 	 
	By:
	 	 	 	 
	Name:

	 	 

	 	 
	Title:
	 	 	 	 

 

Exhibit C

Assignment Form

FOR VALUE RECEIVED, the undersigned owner of this Warrant for the purchase of shares of Common
Stock of ADVENTRX Pharmaceuticals, Inc., a Delaware corporation formerly known as Biokeys
Pharmaceuticals, Inc. (the “Company”) hereby sells, assigns and transfers unto the assignee named
below all of the rights of the undersigned under this Warrant, with respect to the number of shares
of Common Stock set forth below:

	 	 	 
	 

	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	 

(Name and Address of Assignee)

	 	 
	 
	 	 
	 
(Number of Shares of Common Stock)
	 	 

and does hereby irrevocably constitute and appoint                                         attorney-in-fact to register such
transfer on the books of the Company, maintained for the purpose, with full power of substitution
in the premises.

	 	 	 	 
	Dated:
	 	 	 
	 

	 	 	 

	 	 	 
	 

(Print Name and Title)

	 	 
	 
	 	 
	 

(Signature)

	 	 
	 
	 	 
	 

(Witness)

	 	 

NOTICE: The signature on this assignment must correspond with the name as written upon the face of
the Warrant in every particular, without alteration or enlargement or any change whatsoever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]